Agios: the company putting patients at the center of its drug development activities

Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients.

But few firms put patients right at the heart of their activities in the way that US pharma company Agios Pharmaceuticals (Nasdaq: AGIO) does—and is thriving by doing so.

The Boston-based rare disease company can point to the success of its approach. It already markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency in the USA, the first disease-modifying therapy for the rare, lifelong, debilitating hemolytic anemia.